extended those findings by incorporating ECP-treated cells in experimental GvHD, which reverted the established disease through an increase in CD4+CD25+Foxp3+ Treg frequency and de novo Treg generation, while indirectly reducing allogeneic responses of donor effector T cells (90). The gene discussed is CD4; the disease is graft versus host disease.